SCOPUS 정보 검색 플랫폼

American Journal of Cardiovascular Drugs

Volumn 10, Issue 5, 2010, Pages 343-346

Riferminogene pecaplasmide

[No Author Info available]

Author keywords

Research and development; Riferminogene pecaplasmide

Indexed keywords

ANGIOGENIC FACTOR; FIBROBLAST GROWTH FACTOR 1; RIFERMINOGENE PECAPLASMIDE; TEMUSI; UNCLASSIFIED DRUG;

AMPUTATION; ANGIOGENESIS; ARTERY DISEASE; BLOOD FLOW; BLOOD VESSEL; CARDIOVASCULAR GENE THERAPY; CLINICAL TRIAL; DRUG FATALITY; GENE TRANSFER; HUMAN; INJECTION SITE PAIN; ISCHEMIC HEART DISEASE; LIMB ISCHEMIA; MUSCLE CELL; MUSCLE CRAMP; MYASTHENIA; NONHUMAN; PAIN; PARESTHESIA; PERIPHERAL EDEMA; PRIORITY JOURNAL; PROTEIN EXPRESSION; SHORT SURVEY;

CLINICAL TRIALS AS TOPIC; FIBROBLAST GROWTH FACTOR 1; GENE THERAPY; HUMANS; PERIPHERAL ARTERIAL DISEASE; PLASMIDS;

EID: 77957309846 PISSN: 11753277 EISSN: 1179187X Source Type: Journal
DOI: 10.2165/11533480-000000000-00000 Document Type: Short Survey

Times cited : (3)

References (13)

1
- 77957305849
- Vical Incorporated, 26 Jul. 2004
- Vical Incorporated. Vical Receives Milestone From Gencell for Cardiovascular Gene Delivery Applications. http://www.vical.com, 26 Jul. 2004
- Vical Receives Milestone From Gencell for Cardiovascular Gene Delivery Applications

2
- 77957299171
- Vical Incorporated, 28 Sep. 2009
- Vical Incorporated. Vical Licensee Sanofi-aventis Completes Enrollment in Phase 3 Angiogenesis Trial. www.vical.com, 28 Sep. 2009
- Vical Licensee Sanofi-aventis Completes Enrollment in Phase 3 Angiogenesis Trial

3
- 77957301670
- sanofi-aventis, 29 Jul. 2009
- sanofi-aventis. Sanofi-aventis Announces Second Quarter 2009 Results. www.sanofi-aventis.com, 29 Jul. 2009
- Sanofi-aventis Announces Second Quarter 2009 Results

4
- 77957302734
- Vical Incorporated, 20 Sep. 2007
- Vical Incorporated. Vical Licensee Sanofi-aventis Initiates Phase 3 Trial to Reduce Amputations. www.vical.com, 20 Sep. 2007
- Vical Licensee Sanofi-aventis Initiates Phase 3 Trial to Reduce Amputations

5
- 77957294299
- Vical Incorporated, 13 Mar. 2006
- Vical Incorporated. Vical Licensee Sanofi-Aventis Releases Phase 2b Angiogenesis Data and Plans for Phase 3. www.vical.com, 13 Mar. 2006
- Vical Licensee Sanofi-Aventis Releases Phase 2b Angiogenesis Data and Plans for Phase 3

6
- 77957305130
- Vical Incorporated, 11 Feb. 2010
- Vical Incorporated. Vical Reports 2009 Financial Results and Progress in Key Development Programs. www.vical.com, 11 Feb. 2010
- Vical Reports 2009 Financial Results and Progress in Key Development Programs

7
- 77957320727
- sanofi-aventis, 29 Jul. 2010
- sanofi-aventis. EPS growth in Q2 2010. www.sanofi-aventis.us, 29 Jul. 2010
- (2010) EPS Growth in Q2

8
- 77957309492
- Vical Incorporated, 02 May 2006
- Vical Incorporated. Vical Reports First Quarter 2006 Financial Results. www.vical.com, 02 May 2006
- Vical Reports First Quarter 2006 Financial Results

9
- 77957307010
- Sanofi Aventis, Nearly 90% of synergies delivered by end 2005; Dividend increased by 26.7%, 24 Feb. 2006
- Sanofi Aventis. Sanofi-aventis Reports Strong Growth of 25.7% in 2005 Adjusted EPS (1); Nearly 90% of synergies delivered by end 2005; Dividend increased by 26.7%. www.sanofi-aventis.com, 24 Feb. 2006
- Sanofi-aventis Reports Strong Growth of 25.7% in 2005 Adjusted EPS (1)

10
- 77957306021
- Eurekalert, 13 Mar. 2006
- Eurekalert. Study Analyzes Gene Therapy For Patients At High Risk For Amputation. www.eurekalert.org, 13 Mar. 2006
- Study Analyzes Gene Therapy for Patients at High Risk for Amputation

11
- 77957304028
- Final results of a phase I clinical study to evaluate NV1FGF (human FGF-1 expression plasmid) in patients with critical limb ischemia
- May
- Henry T, Comerota AJ, Chronos N, et al. Final results of a phase I clinical study to evaluate NV1FGF (human FGF-1 expression plasmid) in patients with critical limb ischemia. Molecular Therapy 5:289, Part 2, May 2002
- (2002) Molecular Therapy , vol.5 , Issue.2 PART , pp. 289
- Henry, T.¹ Comerota, A.J.² Chronos, N.³

12
- 77957291952
- Intramuscular injection of plasmid DNA encoding fibroblast growth factor-1 induces angiogenesis in a rabbit hindlimb model of peripheral ischaemia
- Abstract Suppl.:, Nov
- Witzenbichler B, Mahfoudi A, Soubrier F, et al. Intramuscular injection of plasmid DNA encoding fibroblast growth factor-1 induces angiogenesis in a rabbit hindlimb model of peripheral ischaemia. European Heart Journal 20 (Abstract Suppl.): 12, Nov. 1999
- (1999) European Heart Journal , vol.20 , pp. 12
- Witzenbichler, B.¹ Mahfoudi, A.² Soubrier, F.³

13
- 77957291953
- Aventis, Pipeline Progress to Help Deliver Sustainable Growth, 18 Jun. 2002
- Aventis. Aventis R&D Day 2002: Seven Potential Blockbusters by 2006; Pipeline Progress to Help Deliver Sustainable Growth. http://www.aventis.com, 18 Jun. 2002
- Aventis R&D Day 2002: Seven Potential Blockbusters by 2006

* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.